Erythropoietin Drugs Market By Drug Class (Biologics and Biosimilar), By Product (Epoetin-Alfa, Epoetin-Beta, Darbepoetin-Alfa, and Others (Pegylated Erythropoietin and Carbamylated Erythropoietin)), By Application (Cancer, Hematology, Renal Diseases, and Neurology), and By Region - Trends, Analysis and Forecast till 2030

The market for erythropoietin drugs was valued at US$11 billion in 2020 and is projected to grow at a compound annual growth rate (CAGR) of 8.9% to reach US$25.9 billion by 2030.

Erythropoietin, also called hematopoietin or hemopoietin, is a hormone the kidney generates that promotes the synthesis of red blood cells in the bone marrow. Antibodies containing erythropoietin are used to treat anemia related to HIV, multiple myeloma, and cancer. Researchers using recombinant DNA technology create synthetic forms of erythropoietin, such as epoetin alfa, beta, delta, and omega. Erythropoietin levels that are normal range from 4 to 24 mU/ml (milliunits per milliliter). Medication known as erythropoiesis-stimulating drugs cause the bone marrow to produce red blood cells. They are used to treat anemia brought on by chemotherapy, end-stage renal disease, surgery, and some HIV/AIDS medications. Under these circumstances, they lessen the need for blood transfusions.